Non-nucleoside inhibitors of HIV reverse transcriptase: screening successes--clinical failures.
A little less than two years ago, the first report describing non-nucleoside inhibitors of HIV reverse transcriptase (RT) led to the high anticipation that a range of new drugs could soon be available for the treatment of AIDS. The intervening period has given rise to several such agents but recent clinical trial data has indicated this optimism to be premature. This short review seeks to trace the brief history of the drug discovery process and to assess whether there are lessons to be learnt from the episode.
D000998:Antiviral Agents / Q000494:pharmacology*; D001665:Binding Sites; D004353:Drug Evaluation, Preclinical; D006678:HIV / Q000187:drug effects* / Q000201:enzymology; D006801:Humans; D018894:Reverse Transcriptase Inhibitors; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D018894:Reverse Transcriptase Inhibitors